Stem Cells for COVID-19. The injection of mesenchymal stem cells derived from the umbilical cord safely reduces the risk of death. Accelerates the recovery time of the most severe COVID-19 patients.
This is based on an innovative study conducted by Researchers from the Miller School of Medicine. The University of Miami. Published in the journal STEM CELLS Translational Medicine.
The study focused on 24 patients hospitalized at the University of Miami or Jackson Memorial Hospital. All were hospitalized with severe respiratory distress due to COVID-19.
Each patient received two injections, several days apart, of mesenchymal stem cells or a placebo. “It was a double-blind study.
“It was explained by Camillo Ricordi. One of the main authors of the study, that neither the doctors nor the patients knew what was being injected. “The treatment group received two injections of 100 million stem cells. Each within three days, totaling 200 million cells per subject.
The researchers found that the treatment was safe, with no serious adverse effects.
One month later, the survival rate of patients in the group treated with stem cells was 91 percent. In the other group, it was 42 percent.
Coronavirus, COVID, Stem Cells, Injection Among patients under 85 years old. All those treated with mesenchymal stem cells survived after one month. Recovered and returned home within two weeks after the last treatment. By day 30, 80 percent of the treatment group had recovered.
“The umbilical cord contains progenitor stem cells or mesenchymal stem cells. With a single umbilical cord, it is possible to provide therapeutic doses for more than 10,000 patients. “It is a unique resource of cells that researchers are investigating for possible use in cell therapy applications. Whenever they need to modulate immune or inflammatory responses,” he said.
Mesenchymal cells to restore normal immune response
Mesenchymal cells not only correct deviated immune and inflammatory responses but also promote tissue regeneration. “The results are vital not only for COVID-19 but also for other diseases. Characterized by aberrant, hyperinflammatory immune responses, such as autoimmune type 1 diabetes.”
When administered intravenously, mesenchymal stem cells naturally migrate to the lungs. Providing therapy for COVID-19 patients with acute respiratory distress syndrome.
Various countries worldwide have initiated multiple studies with stem cells in patients with COVID-19 pneumonia, aiming to explore potential treatments. These studies propose the use of diverse sources of stem cells such as bone marrow, fat, or placenta. The results are particularly relevant and promising.
We invite you to read our article stem cells to learn more.